Chugai Pharmaceutical Co., Ltd. Stock OTC Markets
Stocks
CHGCY
US1712691039
Pharmaceuticals
OTC Markets Traded|
Market Closed -
OTC Markets
16:00:00 2026-09-10 EDT
|
5-day change | 1st Jan Change | ||
| 20.51 USD | -1.91% |
|
-6.73% | -21.93% |
| 08-21 | Alvotech Enters Licensing, Commercialization Deal for Two Biosimilars in US, Certain Asian Markets | MT |
| 08-17 | Chugai grants GSK exclusive global license for AID351 dengue antibody | AN |
| Market Cap | 10,560B 68.56B 58.96B 55.63B 50.68B 94.73B 6,554B 95.59B 663B 255B 3,325B 257B 252B | P/E 2026 * |
20.9x | P/E 2027 * | 18.1x |
|---|---|---|---|---|---|
| Enterprise Value | 9,649B 62.65B 53.88B 50.83B 46.31B 86.57B 5,989B 87.35B 605B 233B 3,038B 235B 230B | EV / Sales 2026 * |
6.95x | EV / Sales 2027 * | 6.15x |
| Free-Float |
38.12% | Yield 2026 * |
2.12% | Yield 2027 * | 2.42% |
| Markets | Quality | ||
|---|---|---|---|
OTC Markets
| CHGCY | Delayed | |
Boerse Muenchen
| CUP0 | Real-time | |
|
Deutsche Boerse AG
| CUP0 | Delayed |
Last Transcript : Chugai Pharmaceutical Co., Ltd.
| 1 day | -1.91% | ||
| 1 week | -6.73% | ||
| Current month | -4.83% | ||
| 1 month | -7.70% | ||
| 3 months | -11.90% | ||
| 6 months | -32.35% | ||
| Current year | -21.93% |
| 1 week | 20.08 |  | 22.05 |
| 1 month | 20.08 | | 23.39 |
| Current year | 20.08 | | 34.84 |
| 1 year | 20.08 | | 34.84 |
| 3 years | 13.85 | | 34.84 |
| 5 years | 10.99 | | 34.84 |
| 10 years | 4.49 | | 100 |
| Manager | Title | Age | Since |
|---|---|---|---|
Osamu Okuda
CEO | Chief Executive Officer | 63 | 2021-02-28 |
Iwaaki Taniguchi
DFI | Director of Finance/CFO | 59 | 2024-03-27 |
Kazuhiko Nishi
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Osamu Okuda
BRD | Director/Board Member | 63 | 2020-02-29 |
Iwaaki Taniguchi
BRD | Director/Board Member | 59 | 2024-03-27 |
| Director/Board Member | 51 | 2025-02-28 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.91% | -6.73% | - | - | 69.38B | |
| -0.11% | -3.16% | +48.82% | +91.49% | 1,002B | |
| -0.27% | -4.34% | +51.52% | +65.89% | 644B | |
| +1.63% | -2.00% | +20.49% | +71.12% | 443B | |
| -0.63% | -3.09% | +29.84% | +34.59% | 343B | |
| +0.43% | -14.61% | +11.32% | +27.26% | 262B | |
| +0.93% | -3.19% | -1.31% | +8.41% | 245B | |
| -2.25% | -13.88% | +37.33% | +47.43% | 212B | |
| -0.90% | -5.06% | -18.47% | -57.75% | 199B | |
| -0.58% | -4.24% | +25.65% | +90.54% | 181B | |
| Average | -0.30% | -5.18% | +22.80% | +42.11% | 392.19B | |
| Weighted average by Cap. | +0.03% | -4.39% | +31.98% | +57.11% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 1,388B 9.01B 7.75B 7.31B 6.66B 12.45B 862B 12.57B 87.1B 33.52B 437B 33.85B 33.11B | 1,529B 9.93B 8.54B 8.05B 7.34B 13.72B 949B 13.84B 95.92B 36.92B 481B 37.27B 36.46B |
| Net income | 506B 3.29B 2.83B 2.67B 2.43B 4.54B 314B 4.58B 31.76B 12.23B 159B 12.34B 12.07B | 583B 3.79B 3.26B 3.07B 2.8B 5.23B 362B 5.28B 36.6B 14.09B 184B 14.22B 13.91B |
| Net Debt | -910B -5.91B -5.08B -4.79B -4.37B -8.16B -565B -8.24B -57.1B -21.98B -287B -22.19B -21.7B | -1,151B -7.47B -6.43B -6.06B -5.52B -10.32B -714B -10.42B -72.2B -27.79B -362B -28.06B -27.44B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-09-10 | US$20.51 | -1.91% | 321,059 |
| 26-09-09 | US$20.91 | -0.67% | 232,810 |
| 26-09-08 | US$21.05 | -2.50% | 187,077 |
| 26-09-04 | US$21.59 | -1.82% | 70,223 |
| 26-09-03 | US$21.99 | +1.95% | 281,890 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- 4519 Stock
- CHGCY Stock
Select your edition
All financial news and data tailored to specific country editions
